BRIM Biotechnology Company Description

BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases.

The company’s lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States.

It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis.

The company was founded in 2013 and is based in Taipei, Taiwan.

BRIM Biotechnology, Inc.

Country	Taiwan
Founded	2013
Industry	Biotechnology
Sector	Healthcare
CEO	Wenqi Xu

Contact Details

Address: No.1, Alley 30 Taipei, 11492 Taiwan
Phone	886 2 2659 8586
Website	brimbiotech.com

Stock Details

Ticker Symbol	6885
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006885007
SIC Code	2836

Key Executives

Name	Position
Dr. Wenqi Xu Ph.D.	Chief Executive Officer and GM
Dr. Haishan Jang M.B.A., Ph.D.	Vice Chairman and Chief Global Strategist
Jiadian Yan	Vice President of Finance and Accounting Supervisor
Kuo Mei-Hui M.S.	Chief Operating Officer
Cheng-Wen Lin Ph.D.	Chief Technology Officer
Dr. Frank W. Lee Ph.D.	Chief Scientific Officer